Cigna (CI) Soars 6.3%: Is Further Upside Left in the Stock?
Werte in diesem Artikel
Cigna (CI) shares ended the last trading session 6.3% higher at $282.41. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 17.7% loss over the past four weeks.Cigna’s recent price movement stems from recovering investor confidence in the prospects of the company after an overreaction by investors to the new resolution targeting pharmacy benefit managers. These provisions were initially feared to impose stringent regulations on the healthcare sector. However, the changes are anticipated to be less severe, and the core business outlook for Cigna remains robust, fueling investor confidence.The company expects the 2024 EPS to be at least $28.40, which indicates growth of 13.2% from the 2023 reported figure. Strong Evernorth Health Services and Cigna Healthcare segments are expected to buoy Cigna’s results and price performance. However, ongoing monitoring of broader market conditions and regulatory changes will be crucial to determining whether further significant stock gains are possible. This health insurer is expected to post quarterly earnings of $7.84 per share in its upcoming report, which represents a year-over-year change of +15.5%. Revenues are expected to be $62.88 billion, up 22.9% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For Cigna, the consensus EPS estimate for the quarter has been revised marginally lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on CI going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Cigna is part of the Zacks Medical - HMOs industry. Molina (MOH), another stock in the same industry, closed the last trading session 1.7% higher at $296.59. MOH has returned 3.3% in the past month.For Molina, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $5.81. This represents a change of +32.7% from what the company reported a year ago. Molina currently has a Zacks Rank of #3 (Hold).Zacks Naming Top 10 Stocks for 2025Want to be tipped off early to our 10 top picks for the entirety of 2025?History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cigna Group (CI): Free Stock Analysis Report Molina Healthcare, Inc (MOH): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf The Cigna Group Registered
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf The Cigna Group Registered
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu The Cigna Group Registered Shs
Analysen zu The Cigna Group Registered Shs
Datum | Rating | Analyst | |
---|---|---|---|
20.07.2018 | Express Scripts Neutral | Robert W. Baird & Co. Incorporated | |
08.03.2018 | Express Scripts Equal Weight | Barclays Capital | |
08.03.2018 | Cigna Overweight | Barclays Capital | |
31.01.2018 | Express Scripts Outperform | RBC Capital Markets | |
15.12.2017 | Express Scripts Outperform | Robert W. Baird & Co. Incorporated |
Datum | Rating | Analyst | |
---|---|---|---|
08.03.2018 | Cigna Overweight | Barclays Capital | |
31.01.2018 | Express Scripts Outperform | RBC Capital Markets | |
15.12.2017 | Express Scripts Outperform | Robert W. Baird & Co. Incorporated | |
14.12.2017 | Express Scripts Buy | Maxim Group | |
04.12.2017 | Express Scripts Buy | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
20.07.2018 | Express Scripts Neutral | Robert W. Baird & Co. Incorporated | |
08.03.2018 | Express Scripts Equal Weight | Barclays Capital | |
19.09.2017 | Express Scripts Sector Perform | RBC Capital Markets | |
21.07.2017 | Express Scripts Hold | Needham & Company, LLC | |
26.04.2017 | Express Scripts Hold | Edward Jones |
Datum | Rating | Analyst | |
---|---|---|---|
22.02.2016 | Express Scripts Sell | Deutsche Bank AG | |
13.01.2009 | CIGNA sell | Citigroup Corp. | |
07.11.2007 | CIGNA underweight | Lehman Brothers Inc. | |
02.11.2006 | Update CIGNA Corp.: Underweight | Lehman Brothers |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für The Cigna Group Registered Shs nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen